Dr. Danielle K. Moul, MD

Dr. Moul practices at Orchard Creek Surgery Center - Mountain View in Mountain View, California.

Dr. Moul's NPI, 1700091113, was assigned on May 11, 2007. Dr. Moul graduated from University of Maryland School of Medicine - Baltimore in 2002. Dr. Moul holds California license A104213.

Dr. Moul's primary practice is Orchard Creek Surgery Center - Mountain View, at 525 South Drive, Suite 115, Mountain View, CA 94040. The practice phone is (650) 969-5600.

Dr. Moul's primary practice is Orchard Creek Surgery Center - Mountain View in Mountain View, California. The medical group on file is Schweiger Dermatology Group, San Pedro. Dmand AI also links Dr. Moul to 3 more medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Moul practices, 3 sites in all. Vendor and product names are available with a free account.

Mohs-micrographic surgery is Dr. Moul's primary specialty in the NPI Registry, under taxonomy code 207ND0101X. Dr. Moul is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Moul's licenses on file in 3 states: California, Arizona and Ohio.

Dmand AI lists benign or precancerous skin growths and contact dermatitis among the conditions Dr. Moul treats.

CMS data shows 2,159 Medicare services from Dr. Moul across 20 procedure codes in 2024, for 272 Medicare patients. Medicare paid $318,832 for them. Every service was in an office.

CMS counts 272 Medicare patients who saw Dr. Moul in 2024. The largest group is 75 to 84, with 116 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 12% are also on Medicaid. Their average risk score is 1.27, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Moul's median patient age at 72, with 52% women.

In 2024, Dr. Moul wrote 802 Medicare Part D claims for 344 patients. 98% of them were for generic drugs. CMS names the drug for 742 of them, across 12 drugs with 11 or more claims each, at $12,523 in total drug cost. In 2022, CMS named 437 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Moul for performance year 2024, reported individually. Dr. Moul accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 51 procedures of melanoma (skin cancer) excision by Dr. Moul, more than 87% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 7 papers to Dr. Moul, published from 2008 to 2013. The most frequent topics are Alefacept, Recombinant Fusion Proteins and Psoriasis. Dr. Moul has published most often in J Am Acad Dermatol. Dr. Moul's most frequent co-authors are Hubert T. Greenway, MD, Peggy Lee Ann Chern, MD and Peter Randall Shumaker, MD.

CMS Open Payments shows 53 general payments to Dr. Moul from 21 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 92% of the total. Abbvie Inc. paid the most, $181.

Dmand AI lists 1 award for Dr. Moul.

Dr. Moul graduated from University of Maryland School of Medicine - Baltimore in 2002. Dr. Moul is a member of AAD.

Dr. Moul is in network with 16 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.